When adjusting for age ≥ 65 at diagnosis (which was a significant predictor of OS in the univariable model, see Table 2), disease stage, and TP53 aberration, intermediate/high risk CLL-CI patients had shorter OS at borderline significance levels (n = 165; intermediate vs. low risk: HR = 4.59 [95%CI, 1.00-20.96], p = 0.049; high vs. low risk: HR = 3.99 [95%CI, 0.85–18.68], p = 0.079; c-index = 0.70). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.